OSI Pharma estimates cut by Merrill Lynch

OSI Pharmaceuticals Inc. was maintained by Merrill Lynch analyst Eric Ende at a buy rating with a price target on the stock of $51 per share, but sales estimates for its eye treatment Macugen were reduced following news of Genentech Inc.'s plan to file approval for its eye treatment Lucentis in December without fast-track status. Merrill believes Lucentis could hurt OSI Pharma's sales of Macugen, and lowered its sales estimates for Macugen to $350 million from $365 million in 2006. OSI Pharma shares Thursday were down $0.84, or 2.52%, at $32.54 on volume of 1,568,717 shares versus the three-month running average of 2,065,040 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.